Last reviewed · How we verify
Ciclosporin soft capsules
Ciclosporin is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines.
Ciclosporin is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines. Used for Organ transplant rejection prophylaxis, Autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, atopic dermatitis), Nephrotic syndrome.
At a glance
| Generic name | Ciclosporin soft capsules |
|---|---|
| Sponsor | Chinese PLA General Hospital |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin (protein phosphatase 2B) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Ciclosporin binds to cyclophilin and inhibits calcineurin phosphatase, preventing dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the production of interleukin-2 and other cytokines essential for T-cell proliferation and immune response, making it a potent immunosuppressant used to prevent organ rejection and treat autoimmune conditions.
Approved indications
- Organ transplant rejection prophylaxis
- Autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, atopic dermatitis)
- Nephrotic syndrome
Common side effects
- Nephrotoxicity
- Hypertension
- Tremor
- Gingival hyperplasia
- Hirsutism
- Headache
- Infection
- Hyperkalemia
Key clinical trials
- Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy (PHASE3)
- Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy (PHASE4)
- Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia (PHASE2)
- Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers (PHASE1)
- A Trial of Hetrombopag in Healthy Subjects (PHASE1)
- Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome (PHASE4)
- Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects (PHASE1)
- Everolimus in de Novo Kidney Transplant Recipients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ciclosporin soft capsules CI brief — competitive landscape report
- Ciclosporin soft capsules updates RSS · CI watch RSS
- Chinese PLA General Hospital portfolio CI